Investment case
Aptevo Therapeutics Inc.
APVO · 3 developments mapped · last assessed 2026-09-03
Market Ontology has mapped 3 macro, policy, and market developments to Aptevo Therapeutics Inc. since 2026-08-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for APVO yet, so no modelled value is shown. The APVO valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run APVO on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AML
Direct positive clinical trial results for lead candidate, increasing probability of regulatory approval and future commercialization.
· Moves probability of success (pos) for mipletamig, peak sales estimates for mipletamig, discount rate (reflecting reduced risk)
- Open question
Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.
Dilution from equity issuance; long-term success of collaboration is uncertain.
· Moves future share count, long term success rate of new drug development
What changed, by assumption
- 2026-09-03Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AML
- 2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.
- 2026-08-14Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc.
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-14 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-08-14 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-03 | Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AML | Bullish | 1-3m | 0.90 |
| 2026-08-14 | Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc. | Bullish | 1-3m | 0.70 |
| 2026-08-14 | Niowave Makes Strategic Equity Investment in Aptevo Therapeutics Inc. | mixed | 1-5y | 0.40 |